Friday, December 07, 2018 12:12:27 PM
So, if clinical trials go well on or around Jan 1, 2019 the product will be able to be developed en-masse (the last 10-Q mentions using 3-d printing to rapidly develop the prototypes that will be first used in the industry).
VNTH will need either a private placement or a cash advance from a "related party" (Nanobeak) in order to pay off the short-term convertible debt so that the class C and class D shares become convertible. Once this is done the company can go current start selling products and developing more and more apps and other IP to use the sensor in other areas (opioids, VOC's, etc.).
Once the debt is wiped clean and the company is current and in business the sky is truly the limit here.
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM